Tag: Pharmaceutical Technology Award

Shivani Chib | Pharmaceutical Science | Young Scientist Award

Published on by World Science Awards

Young Scientist Award

Shivani Chib — Central University of Punjab

Shivani Chib
Affiliation Central University of Punjab
Country India
Scopus ID 57946271800
Documents 24
Citations 315
h-index 10
Subject Area Pharmaceutical Science
Event World Science Awards
Google Scholar ID 8hFOqyEAAAAJ

Shivani Chib is a researcher affiliated with the Central University of Punjab, India, whose stated subject area is Pharmaceutical Science. Available bibliographic information identifies 24 documents, 315 citations, and an h-index of 10 in the supplied Scopus profile. These indicators provide a quantitative overview of the research record represented in the cited author profile. [1]

This academic recognition page presents the research profile in the context of the Young Scientist Award associated with the World Science Awards. The article is intended as a structured scholarly summary and distinguishes bibliographic indicators from broader qualitative considerations of research contribution and relevance. [3]

Abstract

Shivani Chib is associated with the Central University of Punjab and works within the broad field of Pharmaceutical Science. The supplied bibliometric record reports 24 documents, 315 citations, and an h-index of 10. [1] These measures can be used to describe the documented visibility and citation history of the research output represented by the identified Scopus author profile. The researcher is considered in relation to the Young Scientist Award under the World Science Awards, with the available information supporting an assessment based on research activity, scholarly output, and bibliometric indicators. [3]

Keywords

  • Young Scientist Award
  • Shivani Chib
  • Pharmaceutical Science
  • Pharmaceutical Research
  • Bibliometrics
  • Research Impact
  • Central University of Punjab
  • World Science Awards

Introduction

Pharmaceutical Science encompasses interdisciplinary research concerned with the discovery, development, formulation, evaluation, and application of pharmaceutical products and related technologies. Researchers working in this field contribute to the scientific evidence base that supports advances in medicines, drug delivery, pharmaceutical analysis, and associated areas of biomedical research.

Within this broader academic context, Shivani Chib is identified with the Central University of Punjab in India. The supplied research record indicates a body of 24 documents and a citation count of 315, alongside an h-index of 10. [1] Such indicators are useful for describing publication and citation activity, although they do not independently establish the quality, originality, or practical significance of individual research contributions.

Research Profile

The available profile information places Shivani Chib within Pharmaceutical Science and identifies the Central University of Punjab as the institutional affiliation. The Scopus author identifier supplied for the researcher is 57946271800. [1] The corresponding Google Scholar identifier is 8hFOqyEAAAAJ, providing an additional route for locating scholarly material associated with the researcher. [2]

Bibliometric indicators should be interpreted in relation to publication age, disciplinary citation practices, authorship patterns, journal characteristics, and the nature of the research questions addressed. Consequently, the reported values are best treated as descriptive indicators rather than as a complete evaluation of scientific merit.

Research Contributions

The supplied information identifies Pharmaceutical Science as Shivani Chib’s principal subject area. On the basis of the available bibliographic record, the research profile can be considered within the wider pharmaceutical research ecosystem, where scholarly contributions may involve experimental investigation, pharmaceutical development, analytical approaches, formulation research, or related interdisciplinary work. Specific research contributions should be assessed from individual publications and their associated abstracts, methods, results, and citation contexts rather than inferred solely from aggregate metrics.

These elements provide a concise quantitative and institutional description of the research profile. A complete scholarly evaluation would additionally consider the originality of individual studies, methodological rigor, reproducibility, collaboration, research relevance, and contributions to scientific knowledge.

Publications

The supplied Scopus information reports 24 documents associated with Shivani Chib’s author profile. [1] Because individual publication titles, journal names, publication years, article types, and DOI identifiers were not provided in the source information supplied for this article, this section does not assign specific publications or DOI records to the researcher without verification.

The complete publication record can be consulted through the researcher’s Scopus author profile and Google Scholar profile. These databases can provide publication-level information, citation records, author associations, and other bibliographic details. [1] [2]

Research Impact

The supplied bibliometric record reports 315 citations across 24 documents, producing an average of approximately 13.1 citations per document when calculated from the provided values. The reported h-index of 10 indicates that, within the cited record, at least ten publications have each received at least ten citations under the applicable indexing and counting conditions. [1]

Citation indicators can help describe scholarly visibility but should not be treated as standalone measures of research quality or societal impact. Citation patterns vary substantially among disciplines and publication types. A broader assessment of impact may include scientific influence, methodological contributions, collaboration, translation into practice, educational value, and relevance to pharmaceutical research.

Award Suitability

The Young Scientist Award associated with the World Science Awards provides a recognition framework in which research activity, scholarly contributions, academic development, and evidence of research influence may be considered. [3] Based on the supplied information, Shivani Chib has a documented research profile in Pharmaceutical Science, an institutional affiliation with the Central University of Punjab, 24 reported documents, 315 citations, and an h-index of 10. [1]

These characteristics provide a reasonable bibliometric basis for consideration within an early-career or young-scientist recognition context. Final award suitability, however, should be determined using the official award criteria and a complete evaluation of the researcher’s publications, originality, scientific contribution, academic trajectory, and supporting documentation rather than bibliometric indicators alone. [3]

  1. Verified bibliographic and citation information should be considered from the relevant scholarly databases.
  2. Individual publications should be reviewed for originality, methodological quality, and contribution to Pharmaceutical Science.
  3. The official World Science Awards criteria should be used for the final award assessment.

Conclusion

Shivani Chib is a Pharmaceutical Science researcher affiliated with the Central University of Punjab, India. The supplied Scopus record identifies 24 documents, 315 citations, and an h-index of 10, providing a measurable overview of the research activity represented by the profile. [1] The available information supports consideration of the researcher in connection with the Young Scientist Award, while a comprehensive award decision should incorporate publication-level evidence and the official evaluation criteria of the World Science Awards. [3]

References

    1. Elsevier. (n.d.). Scopus author details: Shivani Chib, Author ID 57946271800. Scopus.
      https://www.scopus.com/pages/authors/57946271800

Preeti Korram | Pharmaceutical Science | Best Researcher Award

Published on by World Science Awards

Best Researcher Award

Preeti Korram
Columbia Institute of Pharmacy, Tekari, Raipur (C.G)
Preeti Korram
Affiliation Columbia Institute of Pharmacy, Tekari, Raipur (C.G)
Country India
Scopus ID 60558174600
Documents 3
Subject Area Pharmaceutical Science
Event World Science Awards

The Best Researcher Award recognizes researchers who demonstrate meaningful contributions to scientific scholarship through research activity, publication, innovation, and professional engagement. Preeti Korram, affiliated with the Columbia Institute of Pharmacy, Tekari, Raipur (C.G), has an indexed research profile in the field of Pharmaceutical Science. The available Scopus record documents three scholarly publications, reflecting participation in the international research literature and an emerging academic contribution to pharmaceutical research.[1]

Abstract

Preeti Korram is a researcher associated with the Columbia Institute of Pharmacy, Tekari, Raipur (C.G), India, with a research focus in Pharmaceutical Science. Her indexed academic record includes three Scopus documents, indicating participation in peer-reviewed scholarly communication. Pharmaceutical Science encompasses drug discovery, formulation, pharmacology, pharmaceutical analysis, and related areas that support the development and responsible use of medicines.[1][2]

Keywords

  • Pharmaceutical Science
  • Pharmacy Research
  • Drug Development
  • Pharmaceutical Research
  • Biomedical Science
  • Scientific Publications
  • Academic Research
  • World Science Awards

Introduction

Pharmaceutical Science is an interdisciplinary field concerned with the discovery, development, evaluation, formulation, analysis, and appropriate use of medicines. Research in this area integrates chemistry, biology, pharmacology, pharmaceutics, biotechnology, and clinical sciences. Academic research in pharmaceutical sciences supports the development of safer and more effective therapeutic products while contributing to evidence-based healthcare.[2][3]

Research Profile

The available Scopus information identifies Preeti Korram under author profile 60558174600 and records three scholarly documents. These publications provide evidence of active participation in indexed scientific literature within Pharmaceutical Science. As bibliometric indicators may change over time, the current Scopus author record remains the appropriate source for verifying publication and citation information.[1]

  • Researcher: Preeti Korram.
  • Institution: Columbia Institute of Pharmacy, Tekari, Raipur (C.G).
  • Country: India.
  • Primary subject area: Pharmaceutical Science.
  • Scopus-indexed documents: 3.
  • Scopus Author ID: 60558174600.

Research Contributions

Research in Pharmaceutical Science contributes to multiple stages of the medicine-development pathway, including pharmaceutical formulation, drug characterization, therapeutic evaluation, and quality assessment. The indexed publication record associated with Preeti Korram indicates engagement with scholarly research in this broad discipline. Continued research and publication in pharmaceutical sciences support the generation and dissemination of evidence relevant to medicine and healthcare.[1][3]

Publications

The available research profile records three documents indexed in Scopus. These publications form part of the researcher’s documented scholarly output and indicate participation in internationally indexed academic literature. Specific publication titles, journals, publication dates, citation counts, and digital object identifiers should be verified against the current bibliographic record before being attributed individually.[1]

  • Scopus-indexed scholarly documents: 3.
  • Research area: Pharmaceutical Science.
  • Peer-reviewed scientific communication.
  • Contribution to pharmaceutical and biomedical scholarship.

Research Impact

Research impact in Pharmaceutical Science can be assessed through publication quality, scholarly citations, collaboration, methodological contribution, and potential relevance to pharmaceutical and healthcare practice. The three indexed documents associated with Preeti Korram establish a documented scholarly presence in the field. Citation and other bibliometric indicators should be interpreted alongside qualitative evidence such as research quality, originality, and relevance to the discipline.[1][4]

Award Suitability

Based on the information provided, Preeti Korram demonstrates an established connection to Pharmaceutical Science through institutional affiliation and indexed scholarly publication. The documented Scopus record provides an objective basis for considering research activity and academic participation in an award evaluation. The Best Researcher Award may recognize such contributions when supported by the award’s formal criteria, including research quality, originality, publication record, professional engagement, and broader contribution to pharmaceutical science.[1][5]

Conclusion

Preeti Korram has developed a documented scholarly profile in Pharmaceutical Science through research activity and Scopus-indexed publication. Her affiliation with the Columbia Institute of Pharmacy provides an academic context for continued engagement with pharmaceutical research. The available record of three indexed documents supports recognition of her participation in scientific scholarship, while comprehensive award assessment should consider the full range of academic and professional evidence.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Preeti Korram, Author ID 60558174600. Scopus.
    https://www.scopus.com/pages/authors/60558174600
  2. World Health Organization. (2017). WHO Expert Committee on Specifications for Pharmaceutical Preparations. World Health Organization.
    https://www.who.int/publications
  3. Taylor, K. M. G., & Aulton, M. E. Aulton’s Pharmaceutics: The Design and Manufacture of Medicines. Elsevier.
    DOI: https://doi.org/10.1016/C2018-0-03685-6
  4. Hicks, D., Wouters, P., Waltman, L., de Rijcke, S., & Rafols, I. (2015). Bibliometrics: The Leiden Manifesto for research metrics. Nature, 520, 429–431.
    DOI: https://doi.org/10.1038/520429a
  5. World Science Awards. (n.d.). Official Award Information.
    https://worldscienceawards.com/

Antra Chaudhary | Pharmaceutical Science | Young Scientist Award

Published on by World Science Awards

Young Scientist Award

Antra Chaudhary,
Jamia Hamdard University, New Delhi, India.

Antra Chaudhary
Affiliation Jamia Hamdard University
Country India
Scopus ID 57406830100
Documents 10
Citations 119
h-index 5
Subject Area Pharmacology, Toxicology and Pharmaceutical Science
Event World Science Awards
ORCID 0009-0006-9003-5566

Antra Chaudhary is an Indian pharmacology researcher and doctoral scholar recognized for her contributions to bone pharmacology, oxidative stress, inflammatory disorders, and neuroprotection research. Her academic work has focused extensively on translational pharmacological approaches involving medicinal plants, osteoporosis therapeutics, neuroinflammation, stem cell-based therapies, and molecular signaling pathways associated with disease progression and tissue protection.[1] She is currently pursuing doctoral research at Jamia Hamdard University under the supervision of Prof. Divya Vohora, where her investigations explore the therapeutic potential of natural compounds against glucocorticoid-induced bone damage and postmenopausal osteoporosis.[2]

Abstract

This academic article presents a scholarly overview of the research contributions, scientific achievements, and professional development of Antra Chaudhary, a pharmacology researcher specializing in bone pharmacology, oxidative stress, inflammatory disorders, and neuroprotection. Her research has contributed to understanding molecular signaling pathways associated with osteoporosis, ischemic stroke, rheumatoid arthritis, and mitochondrial dysfunction. Through interdisciplinary pharmacological investigations involving in vitro and in vivo models, her work has emphasized translational therapeutic strategies and the use of bioactive compounds for disease modulation.[3] The article further documents her academic qualifications, awards, technical expertise, scientific publications, and suitability for academic recognition in the field of pharmacology and biomedical sciences.

Keywords

Bone Pharmacology, Oxidative Stress, Osteoporosis, Pharmacology, Neuroprotection, Medicinal Plants, Inflammatory Diseases, Stem Cell Therapy, Molecular Pharmacology, Translational Research, Rheumatoid Arthritis, Glucocorticoid-Induced Bone Damage, Pharmacodynamics, Biomedical Sciences.

Introduction

Contemporary pharmacological research increasingly emphasizes translational approaches that integrate molecular biology, therapeutic intervention, and clinical applicability. Researchers in pharmacology are actively investigating novel compounds and signaling pathways to address chronic diseases, neurodegeneration, inflammatory disorders, and metabolic dysfunctions.[4] Within this scientific landscape, Antra Chaudhary has contributed to emerging research areas involving osteoporosis therapeutics, oxidative stress modulation, neuroinflammation, and medicinal plant-based pharmacological interventions.

Her academic journey reflects a progression through pharmaceutical sciences and toxicology training, supported by competitive national examinations including GPAT and NIPER-JEE. She has participated in multidisciplinary research projects and advanced laboratory investigations utilizing molecular, histological, and imaging-based techniques for experimental pharmacology studies.[5]

Research Profile

Antra Chaudhary completed her Master of Science in Pharmacology and Toxicology from the National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, where she worked on medicinal plant extracts from North-East India for inflammatory disease research. Her doctoral research at Jamia Hamdard University focuses on bone pharmacology and oxidative stress biology under the supervision of Prof. Divya Vohora.[2]

Her technical expertise encompasses a broad range of experimental methodologies, including Western blotting, RT-PCR, immunohistochemistry, fluorescence microscopy, micro-computed tomography, small animal imaging, and cell culture systems. She has also demonstrated competence in pharmacological data analysis using GraphPad Prism and image analysis software.[3]

  • DST WISE KIRAN Fellow for doctoral research in Life Sciences.
  • Qualified GPAT and NIPER-JEE examinations with competitive national rankings.
  • Recipient of the Young Investigator Award 2025 at IPC-IPSCON 2025.
  • Contributor to peer-reviewed journals in pharmacology and neuroscience.

Research Contributions

The scientific contributions of Antra Chaudhary span multiple pharmacological domains, including neuroprotection, osteoporosis, inflammatory signaling, and mitochondrial biology. Her collaborative studies have investigated the role of cardiolipin-mediated mitochondrial protection in ischemic stroke and the therapeutic implications of stem cell-mediated inflammasome modulation.[1]

Her work on bone-targeted daidzein-loaded hydroxyapatite nanoparticles evaluated osteogenic potential and pharmacodynamic activity in postmenopausal osteoporosis models, highlighting nanotechnology-assisted therapeutic delivery systems.[8] Additionally, she contributed to research exploring TLR4/NF-κB and Keap1/Nrf2 signaling pathways in rheumatoid arthritis using perillyl alcohol interventions.[2]

Her review publications further discuss CRISPR/Cas9 technologies in neurological disorders, drug repurposing strategies for stroke intervention, and glial cell responses in neurodegenerative conditions.[5]

Publications

Selected Research Articles

  1. Gautam N, Sharma P, Chaudhary A, et al. Investigating the osteogenic potential of bone-targeted daidzein loaded hydroxyapatite nanoparticles for postmenopausal osteoporosis. Journal of Drug Targeting, 2025.
  2. Sarmah D, Sarkar A, Datta A, et al. Cardiolipin-mediated alleviation of mitochondrial dysfunction is a neuroprotective effect of statin in ischemic stroke. ACS Chemical Neuroscience, 2023.
  3. Puppala ER, Jain S, Saha P, et al. Perillyl alcohol attenuates rheumatoid arthritis via regulating TLR4/NF-κB and Keap1/Nrf2 signaling pathways. Phytomedicine, 2022.

Review Articles

  • Advancement in CRISPR/Cas9 technology to better understand and treat neurological disorders.
  • Drug repurposing for stroke intervention.
  • Glial cells response in stroke.

Research Impact

The research contributions of Antra Chaudhary demonstrate interdisciplinary relevance across pharmacology, neuroscience, and biomedical sciences. Her publications address clinically significant challenges associated with osteoporosis, ischemic stroke, inflammatory diseases, and oxidative stress-mediated tissue injury.[11]

Her collaborative work in molecular pharmacology and translational therapeutics contributes to ongoing scientific efforts aimed at developing safer and more effective treatment strategies. The integration of medicinal plant research, nanotechnology-based drug delivery systems, and cellular signaling investigations highlights the translational significance of her scientific profile.[2]

Award Suitability

Antra Chaudhary’s academic profile reflects sustained engagement in experimental pharmacology, translational biomedical research, and scientific dissemination through peer-reviewed publications and conference presentations. Her recognition through the Young Investigator Award at IPC-IPSCON 2025 further demonstrates professional acknowledgment of her contributions within the pharmacological research community.[3]

Her expertise in advanced laboratory techniques, coupled with her publication record and participation in international scientific activities, supports her suitability for academic recognition in the field of pharmacology and bone research. The interdisciplinary scope of her work aligns with contemporary priorities in therapeutic innovation and disease prevention.

Conclusion

Antra Chaudhary represents an emerging researcher in pharmacology whose scientific activities encompass bone pharmacology, oxidative stress biology, neuroprotection, and translational therapeutics. Through experimental research, scholarly publications, and active participation in scientific conferences, she has contributed to advancing knowledge in multiple biomedical domains. Her work continues to support the development of innovative therapeutic approaches aimed at improving disease management and bone health outcomes.[1]

References

  1. Jamia Hamdard University. (2026). Doctoral Research Profile of Antra Chaudhary.
  2. Jamia Hamdard University. (2026). Bone Pharmacology and Oxidative Stress Research Program.
  3. Elsevier. (2025). Pharmacological approaches in osteoporosis and translational therapeutics.
  4. Drug Discovery Today. (2022). Drug repurposing for stroke intervention.
    https://doi.org/10.1016/j.drudis.2022.03.014
  5. National Institute of Pharmaceutical Education and Research. (2020). MS Research Project Documentation.

Yan Niu | Pharmaceutical Science | Research Excellence Award

Published on by World Science Awards

Prof. Yan Niu | Pharmaceutical Science | Research Excellence Award

Peking University | China

Prof. Yan Niu is a medicinal chemist at Peking University whose research focuses on the discovery and optimization of biologically active small molecules, with special emphasis on hydrophobic tagging–based targeted protein degradation. She has contributed significant advances in amino-acid–derived hydrophobic tags capable of inducing selective POI degradation with mechanisms and pharmacological profiles distinct from PROTACs, expanding the chemical space available for next-generation degraders. With 47 Scopus-indexed publications, 549 citations, and an h-index of 14, her work bridges synthetic chemistry, chemical biology, and drug discovery. She has led competitive national projects, filed three patents, and collaborated internationally in Germany and Austria. Her research provides promising strategies for developing novel therapeutics and deepens mechanistic understanding of protein degradation pathways, contributing to innovation in medicinal chemistry and early-stage drug development.

Citation Metrics (Scopus)

500
450
300
150
0

Citations
549
Documents
47
h-index
14

Citations

Documents

h-index

Featured Publications

 

Omid Mehrpour | Pharmaceutical Science | Editorial Board Member

Published on by World Science Awards

Dr. Omid Mehrpour | Pharmaceutical Science | Editorial Board Member

Wayne State University | United States

Dr. Omid Mehrpour is a distinguished medical toxicologist, clinical data scientist, and physician whose work integrates toxicology, public health, and artificial intelligence to advance diagnostic accuracy and patient outcomes. With over two decades of academic, clinical, and research experience, he has become an internationally recognized expert in poisoning, substance use disorders, and AI-driven medical decision-making. Dr. Mehrpour has authored more than 200 peer-reviewed articles, ten book chapters, and a book translation, accumulating over 4,000 scientific citations. His publications and research outputs have significantly shaped clinical toxicology guidelines globally, particularly in areas related to opioids, heavy metals, aluminum phosphide, cannabinoids, and environmental toxicants. A pioneer in AI-based diagnostic innovation, Dr. Mehrpour developed machine learning–driven protocols for poison diagnosis, leading to two registered U.S. patents and additional patents in Iran for diagnostic software and toxicology devices. His work at the Rocky Mountain Poison & Drug Safety Center and collaborations with national databases such as NPDS and ToxIC contributed foundational methods for rapid identification and triage of poisoning cases. He has also led AI and clinical informatics initiatives at the University of Colorado Anschutz Medical Campus and founded AI and Health LLC to develop intelligent clinical tools that enhance diagnosis and care delivery. Throughout his career, Dr. Mehrpour has held leadership roles including Head of the Medical Toxicology and Drug Abuse Research Center and Director of the Poisoning Ward at Birjand University of Medical Sciences. He has supervised numerous graduate researchers and served on editorial boards of multiple international journals. His contributions have received global recognition, including placement among the top 2% of scientists worldwide, multiple “Top Reviewer” honors from Publons, and numerous national research awards. Dr. Mehrpour’s work continues to elevate the fields of toxicology, predictive modeling, and precision medicine, contributing impactful solutions that improve healthcare systems and advance patient safety worldwide.

Profiles: Scopus | ORCID

Featured Publications

1. Eizadi-Mood, N., Barzam, E., Pirali, Z., Feizi, A., Namvar, M., Abdi, E., Mirmoghtadaee, P., Mehrpour, O., & Meamar, R. (2025). Gender differences in opioid and stimulant poisoning in the central region of Iran: A cross-sectional study. Scientific Reports.

2. Amrollahi-Sharifabadi, M., Oladejo, T. O., Ibrahim, A. S., Shakoor, B., Mehrpour, O., Sadeghi-Hashjin, G., & Gonçalves, S. (2025). Melatonin’s paradox: From therapeutic benefits to toxicity warnings. Chemico-Biological Interactions, 111556.

3. Kooshki, A., Mansouri, B., Farmani, R., Amirabadizadeh, A., Mehrpour, O., Sanjari, M. J., & Nakhaee, S. (2024). Essential and toxic metal concentrations in biological samples of multiple sclerosis patients: A systematic review and meta-analysis. PLOS ONE, 19(12), e0313851.

4. Mehrpour, O., & Sadeghi, M. (2024). The occurrence of unusually cold weather could contribute to the incidence of carbon monoxide poisoning. Clinical and Experimental Emergency Medicine.

5. Nakhaee, S., Kooshki, A., Hormozi, A., Akbari, A., Mehrpour, O., & Farrokhfall, K. (2023). Cinnamon and cognitive function: A systematic review of preclinical and clinical studies. Nutritional Neuroscience.

Ismaeil Haririan | Pharmaceutical Biomaterials | Outstanding Scientist Award

Published on by World Science Awards

Prof. Ismaeil Haririan | Pharmaceutical Biomaterials | Outstanding Scientist Award

Teharn University of Medical Sciences (TUMS), Iran

Prof. Ismaeil Haririan is a distinguished Professor of Pharmaceutics and Pharmaceutical Biomaterials at the Faculty of Pharmacy, Tehran University of Medical Sciences (TUMS), where he also serves as the Founder of the Department of Pharmaceutical Biomaterials and Head of the Biomaterials Research Center. He earned his Pharm.D. from Tabriz University and pursued a Ph.D. in Pharmaceutics at the University of London in 1993, followed by postdoctoral research in targeted drug delivery, which laid the foundation for his lifelong contributions to biomaterials and regenerative medicine. With over three decades of academic and research experience, Prof. Haririan has played a pioneering role in advancing interdisciplinary research that integrates pharmacy, materials science, and biomedical engineering. His research interests span the design of hyaluronic acid hydrogels for bone and cartilage regeneration, 3D pharming and bioprinting, microfluidics in pharmaceutical applications, drug delivery systems, nanomedicine, and pharmaceutical rheology. He has authored more than 120 SCI-indexed articles, earning over 3,600 citations, an h-index of 34, and an i10-index of 65, reflecting the global impact of his work. His research skills extend across tissue engineering, drug delivery system design, nanostructure characterization, and translational medicine, complemented by his strong expertise in mentoring doctoral candidates and industrial trainees. Recognized internationally as a leading figure in pharmaceutical biomaterials, Prof. Haririan has received numerous awards and honors, including recognition as a world leader in bioprinting research between 2022 and 2025. Beyond his scholarly contributions, he has served in editorial capacities, led major research collaborations, and advanced education by supervising Pharm.D. and Ph.D. students. In conclusion, Prof. Haririan embodies academic excellence, visionary leadership, and innovative research, making him one of the most influential scientists in pharmaceutics and biomaterials whose work continues to inspire progress in regenerative medicine and pharmaceutical sciences worldwide.

Profile: Scopus | ORCID

Featured Publications

Al-Jawadri, A. M. H., Karami, Z., Haririan, I., Akrami, M., & Gholami, M. (2025). Development of a bio-inspired phagocytic stable nanoghost with anti-inflammatory properties for management of inflammation in ulcerative colitis. Journal of Drug Targeting, 33(7), 1-15.

Safari, F., Goudarzi, A., Abolghasemi, H., Mohammad, H. A., Akrami, M., Mohammadi, S., & Haririan, I. (2025). Additive manufacturing of regorafenib tablets: Formulation strategies and characterization for colorectal cancer. Polymers, 17(17), 2302.

Sohrabi, R., Miri, A. H., Rad-Malekshahi, M., Saadatpour, F., Pourjabbar, B., Keshel, S. H., Arefian, E., Balalaei, S., Masoumi, A., Khalili, F., Haririan, I., Akrami, M., & Shahriari, M. H. (2025). Corrigendum to “Development of silk fibroin/collagen film containing GI-20 peptide-loaded PLGA nanoparticles against corneal herpes simplex virus-1” [International Journal of Pharmaceutics, 669 (2025), 125022]. International Journal of Pharmaceutics, 674, 125369.

Torabi, M., Haririan, I., Foroumadi, A., Ghanbari, H., & Ghasemi, F. (2024). A deep learning model based on the BERT pre-trained model to predict the antiproliferative activity of anti-cancer chemical compounds. SAR and QSAR in Environmental Research, 35(11), 971-992

Cem Calışkan | Pharmaceutical Science | Best Researcher Award

Published on by World Science Awards

Dr. Cem Calışkan | Pharmaceutical Science | Best Researcher Award

R&D Manager from World Medicine, Turkey

Dr. Cem Çalışkan is an accomplished R&D Manager and pharmaceutical researcher with a distinguished background in analytical chemistry, method development, and regulatory compliance. His professional journey is marked by extensive contributions to the pharmaceutical industry, particularly in analytical method validation, formulation development, and laboratory accreditation processes. With over a decade of progressive experience, Dr. Çalışkan has held key roles at leading pharmaceutical organizations including World Medicine and Neutec İlaç, consistently driving innovation and excellence in pharmaceutical R&D. His academic background features a Ph.D. in Analytical Chemistry from Yıldız Technical University, complemented by a Master’s degree in Organic Chemistry and ongoing Executive MBA studies at Istanbul University, reflecting a multidisciplinary approach to science and leadership. Dr. Çalışkan’s portfolio includes several peer-reviewed publications in top scientific journals, where he explores themes such as nitrosamine detection, impurity profiling, stability-indicating methods, and in-vitro drug release. His research not only addresses critical analytical challenges but also aligns with global regulatory standards. With a passion for mentoring, scientific rigor, and innovation, Dr. Çalışkan exemplifies the integration of academic excellence and industrial impact, making him a strong candidate for scientific recognition at the international level.

Professional Profile

Education

Dr. Cem Çalışkan has a comprehensive and interdisciplinary educational background that has shaped his expertise in analytical and organic chemistry as well as pharmaceutical development. He earned his Doctor of Philosophy (Ph.D.) in Analytical Chemistry from Yıldız Technical University between 2018 and 2022, where he focused on advanced analytical techniques and pharmaceutical applications. His doctoral work provided the foundation for several high-impact scientific publications and patents in method validation and impurity analysis. To complement his scientific expertise with managerial insight, Dr. Çalışkan is currently pursuing an Executive MBA at Istanbul University (2024–present), focusing on strategic business management and leadership in the pharmaceutical industry. His academic journey also includes a Master of Science in Organic Chemistry from Sakarya University (2014–2016), where he deepened his understanding of chemical reactions, drug formulation, and molecular mechanisms. He holds a Bachelor of Science in Chemistry from Uludağ University (2003–2009), which laid the initial groundwork for his professional path in R&D. This strong academic progression, spanning both the sciences and management, enables Dr. Çalışkan to bridge the gap between innovative research and strategic decision-making in the pharmaceutical sector.

Professional Experience

Dr. Cem Çalışkan’s professional experience reflects a sustained commitment to innovation and quality in pharmaceutical research and development. Since 2020, he has been serving as the R&D Manager at World Medicine, where he leads cross-functional teams in analytical development, method validation, and compliance with international regulatory standards. In this role, he initiated the patented WMINOLAB analytical service model, exemplifying his vision for high-quality, independent R&D frameworks. Prior to this, from February to August 2020, he held the position of R&D Analytical Development Chief at the same organization, coordinating sustainable business process models, documentation systems, and team development initiatives. Between 2013 and 2020, Dr. Çalışkan worked as an R&D Responsible Specialist, playing a critical role in analytical method development, stability testing, and responding to regulatory queries from global authorities. Earlier in his career, he served as a Process Development Analyst at Neutec İlaç (2011–2013), where he conducted formulation trials, transfer validations, and documentation for CTD Module III. These roles have not only honed his technical capabilities but also highlighted his strategic thinking, regulatory insight, and project management skills in both domestic and international pharmaceutical landscapes.

Research Interests

Dr. Cem Çalışkan’s research interests center on pharmaceutical analytical chemistry, with a special focus on developing novel methods for impurity profiling, drug stability studies, and nitrosamine risk assessment. He is deeply engaged in creating robust and regulatory-compliant analytical methodologies using cutting-edge instruments such as LC-MS/MS, RP-HPLC, and FTIR spectroscopy. His scientific inquiries aim to improve the accuracy, reproducibility, and efficiency of pharmaceutical testing methods, ensuring safer and more effective drug formulations. A key area of his work involves validating stability-indicating methods for various drug compounds, exploring the physicochemical behavior of active pharmaceutical ingredients (APIs) and excipients under stress conditions. He is also involved in studies on in-vitro drug release, polymer membrane permeability, and analytical compatibility of formulation components. In recent years, Dr. Çalışkan has broadened his scope to include the assessment of genotoxic impurities and packaging-related contaminant analysis, which are critical in modern pharmaceutical safety regulations. His interest in bridging laboratory innovation with regulatory frameworks is reflected in his leadership of accredited research labs and method development teams. This intersection of research excellence and industry relevance defines his contribution to the evolving landscape of pharmaceutical sciences.

Research Skills

Dr. Cem Çalışkan possesses a broad and advanced skill set in pharmaceutical R&D, particularly in the analytical domain. His technical proficiency includes the use of LC-MS/MS, RP-HPLC, FTIR, UV-Vis spectroscopy, and gravimetric analysis for method development, validation, and impurity determination. He is well-versed in Good Laboratory Practice (GLP) and has led numerous method validation studies, including for high-risk pharmaceutical substances like nitrosamines and complex impurities. His skills extend to process optimization, formulation compatibility testing, and the analytical transfer of drug products across laboratories and regulatory environments. Dr. Çalışkan also excels in scientific documentation, protocol writing, and preparation of CTD Module III files for regulatory submission. Beyond technical expertise, he has notable experience in project management, cross-departmental coordination, and team training, equipping him to lead dynamic research teams. His communication skills support effective regulatory correspondence with ministries and international partners, while his analytical thinking aids in critical decision-making across all stages of pharmaceutical development. Combined, these research skills make him not only a technically sound researcher but also an effective scientific leader.

Awards and Honors

While specific awards and honors are not listed in his current profile, Dr. Cem Çalışkan’s career accomplishments reflect a reputation for research excellence and industrial innovation. His leadership in the development and implementation of WMINOLAB, a patented analytical service platform within World Medicine, stands as a testament to his ability to deliver novel, scalable solutions to industry-wide challenges. His publications in reputable journals such as the Journal of Pharmaceutical Sciences, European Journal of Mass Spectrometry, and Journal of AOAC International showcase his academic influence and contributions to pharmaceutical quality control and safety. Additionally, Dr. Çalışkan has played a crucial role in securing and maintaining laboratory accreditations, further evidencing his standing in the professional R&D community. With continued recognition through publications, cross-functional leadership roles, and innovation in analytical techniques, it is evident that he is well-positioned for formal accolades in both industrial and academic circles. Nomination for a Best Researcher Award would be a fitting acknowledgment of his significant impact on pharmaceutical research and method validation at both national and international levels.

Conclusion

Dr. Cem Çalışkan represents a compelling candidate for the Best Researcher Award, bringing together scientific rigor, innovative thinking, and impactful leadership in the pharmaceutical sector. His multi-tiered education, from chemistry through analytical science to business management, empowers him to operate effectively at the intersection of research, industry, and regulation. His extensive experience with analytical method development, impurity profiling, and compliance documentation, along with his proactive approach to laboratory innovation, positions him as a distinguished researcher. His publication record reinforces his scientific credibility, while his managerial roles highlight his ability to lead R&D initiatives with strategic foresight. What sets Dr. Çalışkan apart is not only his technical excellence but also his drive to elevate pharmaceutical research standards in Turkey and beyond. As the industry faces increasing regulatory scrutiny and demands for innovation, his skill set is more relevant than ever. Recognizing his achievements through a Best Researcher Award would honor a career dedicated to advancing analytical science and fostering pharmaceutical innovation, while inspiring emerging researchers to pursue excellence in both academia and industry.

Publications Top Notes

1. Comparison of permeability of topical Cream drug through polymer synthetic membranes of different structures using Franz Cell diffusion test

  • Authors: Cihan Torlak, Müge Güleli, Şevki Kızılok, Remziye Azra Kartop, et al.

  • Year: 2024

  • Journal: Journal of Dispersion Science and Technology

2. Evaluation of a Novel LC‑MS/MS Based Analytical Method for the Risk Assessment of Nitrosamines in Pharmaceutical Products and Packaging Materials

  • Authors: Remziye Azra Kartop, Cihan Torlak, et al. (study led by Kartop and colleagues)

  • Year: 2024

  • Journal: Journal of Pharmaceutical Sciences

3. Simultaneous quantification of tiotropium bromide impurities G + H in capsule formulation by LC‑MS/MS

  • Authors: Not specified in preview

  • Year: 2023

  • Journal: European Journal of Mass Spectrometry

 

 

Sa Xiao | Pharmaceutical Science | Best Researcher Award

Published on by World Science Awards

Dr. Sa Xiao | Pharmaceutical Science | Best Researcher Award

Chief Pharmacist, Clinical pharmacist from The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, China

Sa Xiao is an experienced Clinical Pharmacist currently working at the Department of Pharmacy, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, Guangdong, China. she has dedicated her career to clinical pharmacy with a focus on providing quality patient care and optimizing pharmaceutical practices. Sa Xiao holds a Master’s degree in Pharmacology and a Bachelor’s degree in Pharmaceutical Engineering. Over the past five years and seven months, she has consistently contributed to clinical pharmacy, focusing on improving therapeutic outcomes and pharmaceutical interventions. Sa Xiao’s role places her at the intersection of clinical application and pharmaceutical research, where she works to enhance drug therapy effectiveness and patient safety. Her work contributes directly to hospital-based pharmaceutical care and supports interdisciplinary collaboration in medical settings. Sa Xiao’s background equips her with both theoretical knowledge and practical clinical experience, positioning her as a valuable asset in the healthcare system. While her current profile emphasizes her clinical expertise, expanding her research portfolio could further elevate her impact in the pharmaceutical field. Her dedication, professional growth, and potential for further research contributions make her a promising candidate for recognition in her domain.

Professional Profile

Education

Sa Xiao has built a strong academic foundation that supports her professional excellence in clinical pharmacy. She began her higher education journey at Huzhou Normal University, where she pursued a Bachelor’s degree in Pharmaceutical Engineering from September 2012 to June 2016. This program provided her with essential knowledge of pharmaceutical sciences, drug formulation, and pharmaceutical manufacturing processes. Her education at this stage focused on understanding drug properties, production, and the basic principles that guide pharmaceutical development. After completing her undergraduate studies, Sa Xiao advanced her academic qualifications by enrolling in Guangdong Medical University, where she earned her Master’s degree in Pharmacology from September 2016 to June 2019. This graduate program allowed her to delve deeper into the study of drug actions, mechanisms, and pharmacokinetics. Through her Master’s studies, she developed a comprehensive understanding of clinical pharmacology, which now directly supports her work as a clinical pharmacist. Both her degrees are recognized by the Ministry of Education, China, affirming the academic rigor and credibility of her educational background. Her academic journey demonstrates a seamless transition from pharmaceutical engineering to clinical application, providing her with the necessary expertise to excel in both pharmaceutical sciences and patient-centered clinical practice.

Professional Experience

Sa Xiao has gained substantial professional experience as a Clinical Pharmacist, holding this role since July 2019 at the Department of Pharmacy, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology. With over five years of experience, she has developed a deep understanding of clinical pharmacy operations, patient care protocols, and hospital pharmaceutical services. Her responsibilities likely include reviewing prescriptions, optimizing medication therapies, ensuring the safe and effective use of drugs, and collaborating with medical teams to enhance patient outcomes. Working in a hospital affiliated with a reputable university has provided her with exposure to clinical research, medical education, and interdisciplinary cooperation. Sa Xiao’s experience is not limited to routine pharmacy tasks; her role also requires ongoing learning and adaptation to the latest pharmaceutical guidelines and therapeutic advancements. Her career has been characterized by dedication to improving patient care and supporting evidence-based clinical decisions. While her profile currently focuses on clinical responsibilities, there is potential for her to expand her contributions to include scientific publications, research studies, and leadership in pharmaceutical innovations. Her professional track record reflects commitment, consistency, and the ability to thrive in a demanding healthcare environment.

Research Interest

Sa Xiao’s research interests are rooted in clinical pharmacy and pharmacology, with a focus on optimizing drug therapies, enhancing patient safety, and improving pharmaceutical care within hospital settings. Her academic and professional background suggests a strong interest in therapeutic drug monitoring, drug interactions, and evidence-based medication management. She is likely driven to explore methods for improving the clinical efficacy of pharmacological treatments and minimizing adverse drug reactions. Additionally, she may be interested in research concerning personalized medicine, dosage adjustments for specific patient populations, and clinical outcomes related to pharmaceutical interventions. Her experience as a clinical pharmacist positions her to contribute valuable insights into hospital-based drug management, prescription review processes, and the practical challenges faced in clinical settings. Future research could also include comparative studies on the effectiveness of different pharmacological treatments and the implementation of clinical pharmacy protocols to improve patient care. By aligning her clinical expertise with focused research initiatives, Sa Xiao has the potential to contribute to both national and international discussions in the field of clinical pharmacology and pharmacy practice. Expanding her research interests to cover these areas would significantly strengthen her academic and professional profile.

Research Skills

Sa Xiao possesses a range of research skills that align with her clinical pharmacy background. Her academic training in pharmacology provided her with expertise in drug action mechanisms, pharmacokinetics, and pharmacodynamics, which are essential for conducting clinical pharmaceutical research. She likely has experience in analyzing clinical data, reviewing case studies, and evaluating therapeutic outcomes in real-world settings. Her role as a clinical pharmacist has refined her skills in prescription auditing, patient counseling, and drug therapy evaluation, which contribute to her ability to design practical, patient-focused research projects. Sa Xiao is also expected to be proficient in using clinical databases, medical literature review systems, and pharmacovigilance tools to support her clinical decision-making and potential research activities. Moreover, she may have developed collaborative skills through working with interdisciplinary teams, which are critical for conducting joint clinical studies and implementing hospital-wide pharmaceutical protocols. To further enhance her research portfolio, acquiring advanced skills in statistical analysis, research methodology, and scientific writing would be beneficial. By building on her current skill set and actively participating in research dissemination through conferences and publications, Sa Xiao can establish herself as a leading contributor in the clinical pharmacy research community.

Awards and Honors

At present, no specific awards or honors have been provided for Sa Xiao. However, her sustained commitment to clinical pharmacy over a period of more than five years at a leading university hospital reflects her professional reliability and growing expertise. Although formal recognitions such as research awards, clinical excellence distinctions, or academic honors have not yet been documented, Sa Xiao’s continuous role in a competitive healthcare environment signifies institutional trust in her capabilities. It is possible that she has received internal recognition for her contributions to patient care, medication management, or quality improvement initiatives within her department. Engaging in national or international pharmaceutical competitions, participating in recognized clinical research projects, and contributing to peer-reviewed publications could open avenues for future awards and honors. Earning formal recognition would not only validate her contributions but also help strengthen her professional profile for broader scientific and clinical acknowledgment. Sa Xiao’s consistent career growth and practical impact within the hospital setting suggest that she is well-positioned to achieve significant honors as she continues to expand her involvement in clinical research and professional development activities in the future.

Conclusion

In conclusion, Sa Xiao is a highly capable clinical pharmacist with a strong educational background and valuable experience in the hospital pharmaceutical sector. Her work at The Sixth Affiliated Hospital, School of Medicine, South China University of Technology demonstrates her ability to apply pharmacological knowledge in a clinical environment, directly benefiting patient care and therapeutic practices. While her current profile is predominantly clinical, there is significant potential for her to make substantial research contributions to the field of clinical pharmacy and pharmacology. Sa Xiao’s foundation in pharmaceutical engineering and pharmacology equips her with both theoretical and practical expertise, which can be further advanced through scientific publications, conference presentations, and research collaborations. By actively participating in research dissemination and seeking broader recognition through professional awards, she can enhance her influence within the scientific and medical communities. Sa Xiao’s dedication, clinical precision, and future research potential position her as an emerging contributor to the advancement of pharmaceutical care and clinical pharmacy research. With further academic engagement and research output, she is likely to achieve greater professional recognition and make impactful contributions to the global healthcare landscape.

Publications Top Notes

1. Depression and Suicide/Self-Injury Signals for Weight Loss Medications: A Disproportionality Analysis of Semaglutide, Liraglutide, and Tirzepatide in FAERS Database

  • Journal: Journal of Affective Disorders

  • Publication Date: 2025-06-14

  • Authors: Wang M, Yang Z, Yan M, Liu S, Xiao S

2. Protective Effects of Aqueous Extract of Wampee Fruit Against Anti-Tubercular Drug-Induced Hepatotoxicity in Rats

  • Journal: Journal of Biological Regulators and Homeostatic Agents

  • Publication Date: 2019-01-01

  • Authors: Guan TM, Xiao S, Liu DC, Liao XH, Li WD, Wu KF, Huang R

 

Carolina Batista | Pharmaceutical Science | Women Researcher Award

Published on by World Science Awards

Dr. Carolina Batista | Pharmaceutical Science | Women Researcher Award

Biomedical from Federal University of Rio de Janeiro, Brazil

Dr. Carolina Batista is a distinguished global health physician with over two decades of experience in humanitarian and public health initiatives. Currently serving as the Head of Global Health Affairs at Baraka Impact Finance, she leverages her medical expertise and strategic insight to foster innovative health solutions for underserved populations. Her career commenced in Brazil, where she provided medical care to indigenous communities in the Amazon. In 2007, she joined Médecins Sans Frontières (MSF), undertaking assignments in Somalia, Africa, and Latin America, focusing on neglected tropical diseases (NTDs) and emerging infectious diseases. As Director of MSF’s Brazilian Medical Unit, she led international campaigns, notably for Chagas disease. Subsequently, at the Drugs for Neglected Diseases initiative (DNDi), she spearheaded access frameworks for NTDs across Latin America, influencing public policies and fostering partnerships. Dr. Batista holds a medical degree from Brazil and a master’s in International Public Health from institutions including the Swiss Tropical and Public Health Institute. Her contributions extend to roles on the International Board of MSF, The Lancet COVID-19 Commission, and as a strategic advisor for ISGlobal, reflecting her commitment to health equity and innovation in global health.

Professional Profile

Education

Dr. Carolina Batista’s educational journey is marked by a blend of clinical training and global public health expertise. She earned her medical degree in Brazil, grounding her in clinical practice and primary healthcare delivery. Pursuing a broader impact, she obtained a master’s degree in International Public Health through a collaborative program involving the Swiss Tropical and Public Health Institute, the Institute of Tropical Medicine in Antwerp, and the Royal Tropical Institute in Amsterdam. This multidisciplinary education equipped her with a comprehensive understanding of global health challenges, particularly in infectious and neglected diseases. Further enhancing her capabilities, Dr. Batista pursued advanced studies in management, health and human rights, and policy and advocacy from renowned institutions. This diverse educational background has been instrumental in her ability to design and implement effective health interventions and policies across various international contexts.

Professional Experience

Dr. Carolina Batista’s professional trajectory encompasses significant roles in global health organizations. Her career began in Brazil, providing medical care to indigenous communities in the Amazon. In 2007, she joined Médecins Sans Frontières (MSF), undertaking assignments in Somalia and later serving as Director of the Brazilian Medical Unit, focusing on neglected tropical diseases (NTDs) and emerging infectious diseases. She led international campaigns, notably for Chagas disease, and coordinated MSF’s medical response to COVID-19 in the Navajo Nation, USA. At the Drugs for Neglected Diseases initiative (DNDi), she served as Head of Access and Medical Affairs, developing access frameworks for NTDs across Latin America. Currently, as Head of Global Health Affairs at Baraka Impact Finance, she supports social entrepreneurs in developing innovative health solutions. Dr. Batista also holds positions on the International Board of MSF and serves as a strategic advisor for ISGlobal

Research Interests

Dr. Carolina Batista’s research interests are deeply rooted in global health equity, focusing on neglected tropical diseases (NTDs), health systems in low- and middle-income countries, and access to healthcare for vulnerable populations. She is particularly interested in the development and implementation of innovative financing mechanisms to achieve the Sustainable Development Goals (SDGs), the role of private capital in bridging healthcare access gaps, and the integration of ethical artificial intelligence in health communication. Her work also explores the intersection of migration and health, pandemic preparedness, and the gender gap in healthcare access. Dr. Batista’s research aims to inform policies and practices that enhance healthcare delivery and accessibility for marginalized communities worldwide.

Research Skills

Dr. Carolina Batista possesses a robust set of research skills that encompass both qualitative and quantitative methodologies. Her expertise includes treatment protocols, health systems analysis, diagnostics, and primary care, particularly concerning parasitic and neglected diseases. She is adept at designing and implementing operational research projects, developing access frameworks, and conducting policy analysis. Her skills extend to evaluating health programs, engaging with stakeholders, and advocating for policy changes. Dr. Batista’s proficiency in these areas enables her to contribute effectively to research initiatives aimed at improving health outcomes in underserved populations.

Awards and Honors

Dr. Carolina Batista’s contributions to global health have been recognized through various appointments and memberships. She serves on the International Board of Médecins Sans Frontières (MSF) and is a strategic advisor for the Barcelona Institute for Global Health (ISGlobal). Her role in leading MSF’s medical response to COVID-19 in the Navajo Nation and her involvement in The Lancet COVID-19 Commission underscore her commitment to addressing health crises. Additionally, she chairs the DNDi Latin America board and serves on the boards of The Lancet Migration Latin America, Movement Health Foundation, and Health in Harmony. These positions reflect her leadership and dedication to advancing health equity and innovation.

Conclusion

Dr. Carolina Batista exemplifies a career dedicated to advancing global health equity through clinical practice, research, and policy development. Her extensive experience with organizations like MSF and DNDi, coupled with her strategic role at Baraka Impact Finance, highlights her commitment to improving healthcare access for marginalized populations. Her educational background and research interests inform her holistic approach to health challenges, integrating innovative solutions with traditional practices. Dr. Batista’s leadership roles and board memberships further demonstrate her influence in shaping global health policies and initiatives. Her work continues to inspire and drive progress towards equitable healthcare worldwide.

Publications Top Notes

1. Exposed Subsoil Under Recovery for 30 Years: Influence of Management Strategies on Soil Physical Attributes and Organic Matter

  • Authors: Laura Silva Nantes, Carolina dos Santos Batista Bonini, Melissa Alexandre Santos, Lucas da Silva Alves, Josiane Lourencetti, Alfredo Bonini Neto, José Augusto Liberato de Souza, Gabriel Augusto da Silva Lunardelli, Mariana Bonini Silva, Dayara Vivian Alvares, et al.

  • Year: 2025

2. Accumulated Carbon Fractions in Tropical Sandy Soils and Their Effects on Fertility and Grain Yield in an Integrated Crop–Livestock System

  • Authors: Deyvison de Asevedo Soares, Bianca Midori Souza Sekiya, Viviane Cristina Modesto, Allan Hisashi Nakao, Leandro Alves Freitas, Isabela Malaquias Dalto de Souza, J.H.S. Luz, Fernando Shintate Galindo, Gelci Carlos Lupatini, Gustavo Pavan Mateus, et al.

  • Year: 2023

3. Evolution of Soil Chemical Fertility in an Area under Recovery for 30 Years with Anthropic Intervention

  • Authors: Josiane Lourencetti, Carolina dos Santos Batista Bonini, Marcelo Andreotti, Marlene Cristina Alves, Alfredo Bonini Neto, Melissa Alexandre Santos, Vitor Correa de Mattos Barretto, Roberth Wicleff Rodrigues de Figueredo

  • Year: 2023

4. Long-Term Integrated Systems of Green Manure and Pasture Significantly Recover the Macrofauna of Degraded Soil in the Brazilian Savannah

  • Authors: Carolina dos Santos Batista Bonini, Thais Monique de Souza Maciel, Bruno Rafael de Almeida Moreira, José Guilherme Marques Chitero, Rodney Lúcio Pinheiro Henrique, Marlene Cristina Alves

  • Year: 2023

5. Long-Term Integrated Crop–Livestock–Forestry Systems Recover the Structural Quality of Ultisol Soil

  • Authors: Aline Matos, Carolina dos Santos Batista Bonini, Bruno Rafael de Almeida Moreira, Marcelo Andreotti, Reges Heinrichs, Diogo Tiago da Silva, José Augusto Liberato de Souza, Melissa Alexandre Santos, Cristiana Andrighetto, Gustavo Mateus Pavan, et al.

  • Year: 2022

6. Azospirillum Inoculation of ‘Marandu’ Palisade Grass Seeds: Effects on Forage Production and Nutritional Status

  • Authors: Reges Heinrichs, G.C. Meirelles, L.F. de Melo Santos, M.V. da Silva Lira, A. de Marcos Lapaz, M.A. Nogueira, C. dos Santos Batista Bonini, Filho, A. Moreira

  • Year: 2020

7. Can Palisade and Guinea Grass Sowing Time in Intercropping Systems Affect Soybean Yield and Soil Chemical Properties?

  • Authors: N.R. Costa, Marcelo Andreotti, C.A.C. Crusciol, C.M. Pariz, J.W. Bossolani, A.M.D. Castilhos, C.A.C.D. Nascimento, C.G.D.R. Lima, C. dos Santos Batista Bonini, E.E. Kuramae

  • Year: 2020

8. Effect of Sulfur Sources on Megathyrsus Maximus ‘Mombaça’ Grass Cultivated in a Typic Ultisol

  • Authors: L.F. de Melo Santos, A. de Marcos Lapaz, F.V. Ribeiro, I.V. Ribeiro, G.C. Meirelles, M.V. da Silva Lira, C.V. Soares Filho, C. dos Santos Batista Bonini, A.R. dos Reis, A. Moreira, et al.

  • Year: 2020

9. Soil Compaction in Crop-Livestock-Forest Integration Systems of Five Years of Implantation and Use

  • Authors: J.F.D. Souza, C. dos Santos Batista Bonini, G.P. Mateus, C.T. de Souza, R.L.S. Perusso, F.G. Pedro, G.L. Oliverio

  • Year: 2020

10. Spray Nozzles and Droplet Size Effects on Soybean Canopy Deposits and Stink Bugs Control in West Region of São Paulo State – Brazil

  • Authors: M.A.G.L. Farias, C.G. Raetano, R.G. Chechetto, P.J. Ferreira-Filho, J.C. Guerreiro, C.S.B. Bonini, A.C. Firmino, R.C. Lima, E.P. Prado

  • Year: 2020

​






	


	

	






	
	

		


Yi-Ping Huang | Pharmaceutical Science | Women Researcher Award
			

				Published on  by World Science Awards			

		
	


	

		
Assoc. Prof. Dr. Yi-Ping Huang | Pharmaceutical Science | Women Researcher Award


Associate Professor from Department of Physiology, China Medical University, Taiwan




















Yi-Ping Huang is an accomplished Associate Professor in the Department of Physiology at China Medical University, with over 32 years of experience in both teaching and research. His primary focus is on cancer treatment, specifically investigating the therapeutic effects of natural and synthetic compounds on cancer cells. Over the years, Huang has significantly contributed to the field, publishing numerous peer-reviewed articles and advancing the understanding of cancer treatment mechanisms, particularly apoptosis, DNA damage, and anti-metastasis pathways. His expertise extends to drug synergy, especially in combination with chemotherapy. He has also been involved in teaching innovations in physiology, emphasizing student engagement and educational research. Huang’s extensive research output and leadership in the field have made him a well-respected figure in the scientific community, as reflected in his numerous research projects and academic publications.


Professional Profile



Education


Yi-Ping Huang completed his undergraduate studies in Physiology at Yang-Ming University, laying the foundation for his extensive career in research and academia. His academic journey provided a strong base for his research into cancer treatment and physiological mechanisms. This solid educational background enabled Huang to develop expertise in a range of specialized topics, particularly in the therapeutic effects of natural compounds. Over the years, his continuous learning and commitment to his field have propelled his success, making him an established academic in the study of cancer therapy and physiology.


Professional Experience


Yi-Ping Huang has a long and distinguished career in both academia and research. As an Associate Professor at China Medical University, he has been instrumental in educating students and conducting cutting-edge research on cancer therapy. With over three decades of experience, Huang has led numerous research projects focusing on natural and synthetic compounds in cancer treatment. His role also includes teaching and mentoring students, guiding them in the latest scientific advancements. Huang’s professional experience is marked by extensive publications in high-impact journals, further showcasing his contributions to the scientific community and his leadership in advancing cancer research.


Research Interests


Yi-Ping Huang’s primary research interests revolve around the use of natural and synthetic compounds in cancer therapy. His work explores the mechanisms through which these compounds induce apoptosis, DNA damage, and inhibit metastasis in cancer cells. Huang is particularly focused on understanding how these compounds can synergize with chemotherapy drugs to overcome resistance and improve treatment outcomes. His ongoing research also investigates the therapeutic effects of compounds such as Demethoxycurcumin (DMC), Phenethyl Isothiocyanate (PEITC), and PW06 in various cancer types, including glioblastoma and colon cancer. These areas of interest align with his goal of advancing cancer therapy through the identification and development of novel therapeutic agents.


Research Skills


Yi-Ping Huang’s research skills are extensive and diverse, ranging from molecular biology techniques to cancer therapy research. He possesses a deep understanding of cancer cell biology, particularly in apoptosis, DNA repair, and metastasis inhibition. Huang has demonstrated proficiency in the use of various experimental models to study the effects of natural and synthetic compounds on cancer cells, including in vitro and in vivo models. His expertise extends to studying drug interactions and mechanisms of drug resistance, especially in relation to chemotherapy. Huang’s interdisciplinary approach to research, combining pharmacology, molecular biology, and cancer therapy, has led to groundbreaking studies that have contributed significantly to the field.


Awards and Honors


Throughout his illustrious career, Yi-Ping Huang has received numerous awards and honors that recognize his contributions to the scientific community. His groundbreaking research in cancer therapy, particularly in the use of natural and synthetic compounds, has earned him accolades from academic institutions and scientific organizations. Huang’s work on compounds such as Demethoxycurcumin and Phenethyl Isothiocyanate has been widely recognized in the field of oncology research. His consistent contributions to cancer treatment research and his leadership in academia have earned him recognition as a leading expert in his field, enhancing his reputation as an influential figure in cancer research.


Conclusion


Yi-Ping Huang’s career has been defined by significant contributions to cancer research, particularly in the development and understanding of natural and synthetic compounds as therapeutic agents. His research focuses on the molecular mechanisms of apoptosis, DNA damage, and anti-metastasis, offering potential for groundbreaking advancements in cancer treatment. With over three decades of experience, Huang’s work continues to influence both basic and clinical cancer research. His leadership in academia, coupled with his innovative research, positions him as a respected figure in the scientific community. As he continues to push the boundaries of cancer therapy, his contributions are likely to have a lasting impact on the field.


Publication Top Notes


M084 causes cell cycle arrest and inhibits voltage-gated Na⁺ and K⁺ channels in neuronal N2A cells
Authors: Iat Lon Leong, Chinmin Chuang, Chenghsun Wu, Yukman Leung, Yiping Huang
Year: 2025


2. MCU-i4, a mitochondrial Ca²⁺ uniporter modulator, induces breast cancer BT474 cell death by enhancing glycolysis, ATP production and reactive oxygen species (ROS) burst
Authors: Edmund Cheung So, Louis Wing Cheong Chow, Chinmin Chuang, Yukman Leung, Yiping Huang
Year: 2025


3. Physalin A induces apoptosis through conjugating with Fas-FADD cell death receptor in human oral squamous carcinoma cells and suppresses HSC-3 cell xenograft tumors in NOD/SCID mice
Authors: Fu Shin Chueh, Shengyao Hsu, Kuangchi Lai, Yiping Huang, Wen Tsong Hsieh
Year: 2025


4. PEITC Induces DNA Damage and Inhibits DNA Repair-Associated Proteins in Human Retinoblastoma Cells In Vitro
Authors: Shengyao Hsu, Yiping Huang, Techun Hsia, Fu Shin Chueh, Chaolin Kuo
Year: 2024


5. Armillaria mellea Mycelia Alleviate PM2.5-Induced Pulmonary Inflammation in Murine Models
Authors: Yiping Huang, Yutsen Huang, Huiyu Wu, Chinchu Chen, Chih Ho Lai
Year: 2024


6. RAGE participates in the intracellular transport of Campylobacter jejuni cytolethal distending toxin
Authors: Yufang Chang, Yiping Huang, Chiahuei Chou, Chenghsun Chiu, Chih Ho Lai
Year: 2024
Citations: 2


7. PW06 suppresses cancer cell metastasis in human pancreatic carcinoma MIA PaCa-2 cells via the inhibitions of p-Akt/mTOR/NF-κB and MMP2/MMP9 signaling pathways in vitro
Authors: Yiping Huang, Chunan Yeh, Yishih Ma, Jin Cherng Lien, Wen Tsong Hsieh
Year: 2024
Citations: 2